GlassScriptPhysician profile
Olufemi A Taiwo
NPI 1225005598
$4,552.90
in general payments reported to CMS, 2019-2025
28 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $805 · 2020: $617 · 2021: $736 · 2022: $666 · 2023: $875 · 2024: $723 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,729.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $860.35 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $664.07 | 2019-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $448.16 | 2019-2024 | Rexulti, Abilify Maintena |
| Allergan, INC. | $434.97 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $330.09 | 2019-2025 | Trintellix |
| Tris Pharma INC | $221.89 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Sunovion Pharmaceuticals INC. | $219.03 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $182.89 | 2019-2024 | Uzedy, Austedo Xr, Austedo |
| Lundbeck LLC | $156.93 | 2021-2023 | Abilify Maintena, Rexulti |
| Ironshore Pharmaceuticals INC. | $116.77 | 2019-2024 | Jornay Pm |
| Indivior INC. | $90.97 | 2022-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $90.52 | 2021-2023 | Qelbree |
| Neurocrine Biosciences, INC. | $89.02 | 2019-2023 | Ingrezza |
| Almatica Pharma LLC | $87.85 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Axsome Therapeutics, INC. | $84.91 | 2023-2024 | Auvelity, Sunosi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $84.33 | 2019-2025 | Fanapt, Hetlioz |
| Corium, LLC | $77.09 | 2022-2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.54 | 2022-2024 | Caplyta |
| Alkermes, INC. | $50.93 | 2023-2024 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $45.92 | 2019-2023 | Adzenys Xr-Odt |
| Shire North American Group INC | $38.07 | 2019 | |
| Vertical Pharmaceuticals, LLC | $33.31 | 2019-2024 | Relexxii |
| Avanir Pharmaceuticals, INC. | $28.51 | 2019 | |
| Eisai INC. | $21.70 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.58 | 2024 | Quviviq |
| Brainsway USA INC | $10.50 | 2024 | Brainsway Deep Tms System |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olufemi Taiwo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.